Common questions about Hymovis (FAQ)
Q: Is Hymovis the same as a steroid shot?
No, Hymovis is a different type of injection than a steroid (corticosteroid) shot. Official regulatory documents classify Hymovis as a viscosupplementation agent and a medical device, the active component of which is hyaluronan. Steroid shots, in contrast, are classified as drugs used primarily to help reduce inflammation.
Q: How quickly does Hymovis start to provide relief?
Clinical studies focused on measuring changes in pain and physical function over a period of 6 months (26 weeks) following the two-injection treatment. Official product information does not specify an exact timeframe (such as hours or days) for when patients should expect to feel the initial onset of relief.
Q: Is Hymovis considered a permanent treatment for joint issues?
Hymovis is approved for the temporary treatment of pain related to knee osteoarthritis. The clinical trials supporting its use primarily measured patient outcomes at six months. Long-term data regarding the effects of repeat cycles or relief beyond this initial period is not fully established in the official product information.
Q: How is Hymovis different from just getting hyaluronic acid supplements?
Hymovis is a highly viscoelastic hydrogel that is administered as an intra-articular injection directly into the knee joint by a medical professional. This classification as a medical device for viscosupplementation differs from oral hyaluronic acid supplements, which must be ingested and absorbed through the digestive system.
Q: Is Hymovis a natural substance?
The active ingredient, hyaluronan, is a substance that occurs naturally in the synovial fluid of human joints. However, the hyaluronan used to create the Hymovis product is produced through a process of bacterial fermentation to ensure a high level of purity for the medical application.
Q: What kind of activity can I do immediately after receiving Hymovis?
Official guidelines recommend avoiding any strenuous or prolonged physical activities (for example, more than one hour) for a period of 48 hours following the injection. The regulatory instructions focus on restricting strenuous or prolonged activity, suggesting light activities like walking or driving are generally permissible.
Q: What are the ingredients in Hymovis?
The primary active component is a highly purified form of hyaluronan, specifically known as HYADD4. The full formulation, including inactive ingredients such as buffering salts, is listed in the comprehensive regulatory documentation for the product.
Q: Why are there usually two injections for the Hymovis treatment?
The treatment is administered as a regimen of two injections, separated by one week, because this was the specific dosage schedule that was tested and evaluated for safety and effectiveness in the pivotal clinical trials leading to regulatory approval.
Q: What should I watch out for in terms of a serious reaction to Hymovis?
Hymovis is contraindicated for anyone with a known history of hypersensitivity (severe allergy) to hyaluronate or proteins derived from gram-positive bacteria. Patients are cautioned to be aware of signs associated with a serious allergic reaction (hypersensitivity) as described in official labeling.
Q: Do studies suggest Hymovis works better for mild or severe joint problems?
The clinical studies reviewed for regulatory approval were conducted on adult patients specifically diagnosed with mild to moderate osteoarthritis of the knee. The effectiveness and safety profile for Hymovis have not been established through studies focusing on patients with severe osteoarthritis.
Q: What if the injection site is red or warm a few days after the shot?
Injection site reactions, including pain, swelling, and redness (erythema), are among the most commonly reported side effects. These events are generally described as transient, meaning they typically occur and resolve in the period immediately following the intra-articular injection.
Q: Why is Hymovis only given by a doctor?
Hymovis is a prescription-only, intra-articular injection that requires administration by a licensed medical professional who is trained in accepted aseptic injection techniques to ensure the product is placed correctly into the joint space.
Q: Can I drive myself home after the Hymovis injection?
Official guidelines recommend avoiding only strenuous or prolonged activity for 48 hours following the injection. Driving is generally considered a light activity and is not explicitly prohibited in the official instructions.
Q: Does Hymovis cause weight gain?
Weight gain is not listed as an adverse event in the official prescribing information for Hymovis, according to regulatory documentation.
Q: Is Hymovis safe for people with diabetes?
Official regulatory documents list specific contraindications, such as local infection/skin disease or known allergies to hyaluronate. Systemic conditions like diabetes are not listed as an official contraindication in the product information.
Q: Does Hymovis treatment require a hospital visit?
The regulatory documents require that the treatment be administered by a licensed medical professional trained in injection techniques. The documents do not specify a mandatory location, meaning the procedure can typically be performed in a doctor's office or clinic.
Q: Does Hymovis contain any addictive substances?
Hymovis is classified as a medical device for viscosupplementation, and its active component is hyaluronan. It is not listed as a controlled substance and official documentation does not indicate that it contains any known addictive substances.
Q: Is the main component of Hymovis found naturally in the body?
Yes, the main component of Hymovis, hyaluronan (hyaluronic acid), is a substance naturally found in the human body. It is a key element of the synovial fluid within healthy joints, where it provides lubrication and shock absorption.
Q: Can people with heart conditions or high blood pressure use Hymovis?
The contraindications in the official prescribing information are highly specific, prohibiting use only for local infection, skin disease, or known allergies. Systemic conditions like heart disease or high blood pressure are not listed as formal contraindications in the product documentation.
Q: Is Hymovis considered a regenerative therapy?
Hymovis is classified as a viscosupplementation agent (a medical device). While its mechanism includes anti-catabolic (anti-breakdown) effects, official regulatory documents do not classify it as a regenerative therapy.
Q: Is it mandatory to have an X-ray or MRI before getting Hymovis?
The official indication for use requires a diagnosis of knee osteoarthritis (OA) that has failed to respond to conservative therapies. The regulatory prescribing documents do not specify that a recent X-ray or MRI is a mandatory precondition for administering the injection.
